<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39932215</PMID><DateCompleted><Year>2025</Year><Month>04</Month><Day>15</Day></DateCompleted><DateRevised><Year>2025</Year><Month>04</Month><Day>15</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1530-0358</ISSN><JournalIssue CitedMedium="Internet"><Volume>68</Volume><Issue>5</Issue><PubDate><Year>2025</Year><Month>May</Month><Day>01</Day></PubDate></JournalIssue><Title>Diseases of the colon and rectum</Title><ISOAbbreviation>Dis Colon Rectum</ISOAbbreviation></Journal><ArticleTitle>Cancer Incidence and Mortality in Familial Adenomatous Polyposis Syndrome.</ArticleTitle><Pagination><StartPage>531</StartPage><EndPage>543</EndPage><MedlinePgn>531-543</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/DCR.0000000000003645</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Risk-reducing colectomy in familial adenomatous polyposis syndrome is the standard of care. This has increased the importance of surveillance for extracolonic malignancies in postcolectomy individuals.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">We sought to define the present-day incidence of all cancers and mortality in familial adenomatous polyposis.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">Retrospective longitudinal cohort study.</AbstractText><AbstractText Label="SETTINGS" NlmCategory="METHODS">Two large academic hospitals.</AbstractText><AbstractText Label="PATIENTS" NlmCategory="METHODS">Eligible patients carried an APC pathogenic variant or met clinical criteria for familial adenomatous polyposis.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">Cancer diagnosis, mortality, and associated risk factors.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 358 patients were identified. The percentage who exhibited a classic familial adenomatous polyposis phenotype was 63.7%; 21.2% were de novo, and 82.7% had a colectomy. Colorectal cancer was the most common cancer (n = 59; 16.5%). Colorectal cancer diagnoses were associated with de novo familial adenomatous polyposis (OR 7.8 [95% CI, 3.51-17.35]; p &lt; 0.001). Thyroid, duodenal/small bowel, gastric, and neuroendocrine tumors were reported in 7.5%, 3.1%, 2.8%, and 2.5% of patients, respectively. Rates of cancer were similar in classic and attenuated familial adenomatous polyposis. Thirty-nine patients (10.9%) died at a mean age of 49.6 &#xb1; 17.1 years. Twenty-six deaths were malignancy-related, and colorectal cancer was the leading cause (n = 10). All colorectal cancer-related deaths occurred in individuals with classic familial adenomatous polyposis, and 9 of 10 individuals were not previously diagnosed with the syndrome. Gastric and duodenal/small bowel cancers were the second leading causes (4 deaths each), and all occurred after colectomy. Fifty-nine percent of all deaths were attributable to a familial adenomatous polyposis-related malignancy or morbidity.</AbstractText><AbstractText Label="LIMITATIONS" NlmCategory="CONCLUSIONS">Retrospective clinical data.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Colorectal cancer remains the most common malignancy and cause of death in familial adenomatous polyposis. However, nearly all colorectal cancer-related deaths occurred in individuals unaware of their familial adenomatous polyposis diagnosis, and none occurred in the attenuated syndrome. In patients who had a colectomy, gastric and duodenal/small bowel cancers are now the leading causes of death. See Video Abstract .</AbstractText><AbstractText Label="INCIDENCIA Y MORTALIDAD POR CNCER EN EL SNDROME DE POLIPOSIS ADENOMATOSA FAMILIAR" NlmCategory="UNASSIGNED">ANTECEDENTES:La colectom&#xed;a para reducir el riesgo en el s&#xed;ndrome de poliposis adenomatosa familiar es el est&#xe1;ndar de atenci&#xf3;n. Esto ha aumentado la importancia de la vigilancia de las neoplasias malignas extracol&#xf3;nicas en individuos post-colectom&#xed;a.OBJETIVO:Buscamos definir la incidencia actual de todos los c&#xe1;nceres y la mortalidad en la poliposis adenomatosa familiar.DISE&#xd1;O:Estudio de cohorte longitudinal retrospectivo.ESCENARIO:Dos grandes hospitales acad&#xe9;micos.PACIENTES:Los pacientes elegibles portaban una variante patog&#xe9;nica de APC o cumpl&#xed;an los criterios cl&#xed;nicos para la poliposis adenomatosa familiar.PRINCIPALES MEDIDAS DE RESULTADOS:Diagn&#xf3;stico de c&#xe1;ncer, mortalidad,y factores de riesgo asociados.RESULTADOS:Se identificaron 358 pacientes. El 63,7% presentaban un fenotipo cl&#xe1;sico de poliposis adenomatosa familiar, el 21,2% eran de novo y el 82,7% se hab&#xed;a sometido a una colectom&#xed;a. El c&#xe1;ncer colorrectal fue el c&#xe1;ncer m&#xe1;s com&#xfa;n (n = 59, 16,5%). Los diagn&#xf3;sticos de c&#xe1;ncer colorrectal se asociaron con poliposis adenomatosa familiar de novo (odds ratio 7,8 (IC del 95 % 3,51-17,35; p &lt; 0,001)). Se informaron tumores de tiroides, duodenales/intestino delgado, g&#xe1;stricos y neuroendocrinos en el 7,5 %, 3,1 %, 2,8 % y 2,5 % de los pacientes, respectivamente. Las tasas de c&#xe1;ncer fueron similares en la poliposis adenomatosa familiar cl&#xe1;sica y atenuada. 39 pacientes (10,9 %) murieron a una edad media de 49,6 &#xb1; 17,1 a&#xf1;os. 26 muertes estuvieron relacionadas con neoplasias malignas y el c&#xe1;ncer colorrectal fue la causa principal (n = 10). Todas las muertes relacionadas con c&#xe1;ncer colorrectal ocurrieron en individuos con poliposis adenomatosa familiar cl&#xe1;sica y 9/10 no hab&#xed;an sido diagnosticados previamente con el s&#xed;ndrome. El c&#xe1;ncer g&#xe1;strico y de duodeno/intestino delgado fueron las segundas causas principales (4 muertes cada uno), y todas ocurrieron despu&#xe9;s de una colectom&#xed;a. El 59% de todas las muertes fueron atribuibles a una neoplasia maligna o morbilidad relacionada con la poliposis adenomatosa familiar.LIMITACIONES:Datos cl&#xed;nicos retrospectivos.CONCLUSIONES:El c&#xe1;ncer colorrectal sigue siendo la neoplasia maligna y la causa de muerte m&#xe1;s com&#xfa;n en la poliposis adenomatosa familiar. Sin embargo, casi todas las muertes relacionadas con el c&#xe1;ncer colorrectal ocurrieron en personas que desconoc&#xed;an su diagn&#xf3;stico de poliposis adenomatosa familiar, y ninguna ocurri&#xf3; en el s&#xed;ndrome atenuado. En los pacientes que se sometieron a una colectom&#xed;a, los c&#xe1;nceres g&#xe1;strico y de duodeno/intestino delgado son ahora las principales causas de muerte. (Traducci&#xf3;n-Dr Yolanda Colorado ).</AbstractText><CopyrightInformation>Copyright &#xa9; The ASCRS 2025.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Feldman</LastName><ForeName>Dan</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-7842-4941</Identifier><AffiliationInfo><Affiliation>Division of Gastroenterology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rodgers-Fouche</LastName><ForeName>Linda H</ForeName><Initials>LH</Initials><AffiliationInfo><Affiliation>Center for Cancer Risk Assessment, Cancer Center, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ukaegbu</LastName><ForeName>Chinedu</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-1629-2824</Identifier><AffiliationInfo><Affiliation>Cancer Genetics and Prevention Division, Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Population Sciences, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yurgelun</LastName><ForeName>Matthew B</ForeName><Initials>MB</Initials><Identifier Source="ORCID">0000-0002-6184-9273</Identifier><AffiliationInfo><Affiliation>Cancer Genetics and Prevention Division, Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Population Sciences, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Syngal</LastName><ForeName>Sapna</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0001-5487-7471</Identifier><AffiliationInfo><Affiliation>Cancer Genetics and Prevention Division, Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Population Sciences, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Gastroenterology, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chung</LastName><ForeName>Daniel C</ForeName><Initials>DC</Initials><AffiliationInfo><Affiliation>Division of Gastroenterology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Cancer Risk Assessment, Cancer Center, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D059040">Video-Audio Media</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>02</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Dis Colon Rectum</MedlineTA><NlmUniqueID>0372764</NlmUniqueID><ISSNLinking>0012-3706</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011125" MajorTopicYN="Y">Adenomatous Polyposis Coli</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003082" MajorTopicYN="N">Colectomy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015179" MajorTopicYN="Y">Colorectal Neoplasms</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013964" MajorTopicYN="N">Thyroid Neoplasms</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013274" MajorTopicYN="N">Stomach Neoplasms</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cancer incidence</Keyword><Keyword MajorTopicYN="N">Colorectal cancer</Keyword><Keyword MajorTopicYN="N">Familial adenomatous polyposis</Keyword><Keyword MajorTopicYN="N">Mortality</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>4</Month><Day>15</Day><Hour>18</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>2</Month><Day>11</Day><Hour>12</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>2</Month><Day>11</Day><Hour>8</Hour><Minute>3</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39932215</ArticleId><ArticleId IdType="doi">10.1097/DCR.0000000000003645</ArticleId><ArticleId IdType="pii">00003453-990000000-00867</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Jasperson KW, Patel SG, Ahnen DJ. APC-associated polyposis conditions. Atlas Genet Cytogenet Oncol Haematol. 2017;24:477&#x2013;482.</Citation></Reference><Reference><Citation>Gupta S, Weiss JM, Axel L, et al. NCCN guidelines: genetic/familial high-risk assessment: colorectal, endometrial, and gastric (version 3.2024). National Comprehensive Cancer Network (NCCN). 2023. https://www.nccn.org/guidelines/guidelines-detail?category=2&amp;id=1544 . Accessed January 31, 2025.</Citation></Reference><Reference><Citation>Dinarvand P, Davaro EP, Doan JV, et al. Familial adenomatous polyposis syndrome an update and review of extraintestinal manifestations. Arch Pathol Lab Med. 2019;143:1382&#x2013;1398.</Citation></Reference><Reference><Citation>Aretz S, Uhlhaas S, Caspari R, et al. Frequency and parental origin of de novo APC mutations in familial adenomatous polyposis. Eur J Hum Genet. 2004;12:52&#x2013;58.</Citation></Reference><Reference><Citation>Matsubara T, Beppu N, Ikeda M, et al. Current clinical practice for familial adenomatous polyposis in Japan: a nationwide multicenter study. Ann Gastroenterol Surg. 2022;6:778&#x2013;787.</Citation></Reference><Reference><Citation>Paszkowski J, Samborski P, Kucharski M, Cwali&#x144;ski J, Banasiewicz T, P&#x142;awski A. Endoscopic surveillance and treatment of upper GI tract lesions in patients with familial adenomatous polyposis&#x2014;a new perspective on an old disease. Genes (Basel). 2022;13:2329.</Citation></Reference><Reference><Citation>Yoon JY, Mehta N, Burke CA, et al. The prevalence and significance of jejunal and duodenal bulb polyposis after duodenectomy in familial adenomatous polyposis retrospective cohort study. Ann Surg. 2021;274:e1071&#x2013;e1077.</Citation></Reference><Reference><Citation>B&#xfc;low S, Christensen IJ, H&#xf8;jen H, et al. Duodenal surveillance improves the prognosis after duodenal cancer in familial adenomatous polyposis. Colorectal Dis. 2012;14:947&#x2013;952.</Citation></Reference><Reference><Citation>Mankaney G, Leone P, Cruise M, et al. Gastric cancer in FAP: a concerning rise in incidence. Fam Cancer. 2017;16:371&#x2013;376.</Citation></Reference><Reference><Citation>Yang J, Gurudu SR, Koptiuch C, et al. American Society for Gastrointestinal Endoscopy guideline on the role of endoscopy in familial adenomatous polyposis syndromes. Gastrointest Endosc. 2020;91:963&#x2013;982.e2.</Citation></Reference><Reference><Citation>Cannon AR, Keener M, Neklason D, Pickron TB. Surgical interventions, malignancies, and causes of death in a FAP patient registry. J Gastrointest Surg. 2021;25:452&#x2013;456.</Citation></Reference><Reference><Citation>Nieuwenhuis MH, Lefevre JH, B&#xfc;low S, et al. Family history, surgery, and APC mutation are risk factors for desmoid tumors in familial adenomatous polyposis: an international cohort study. Dis Colon Rectum. 2011;54:1229&#x2013;1234.</Citation></Reference><Reference><Citation>Aelvoet AS, Struik D, Bastiaansen BAJ, et al. Colectomy and desmoid tumours in familial adenomatous polyposis: a systematic review and meta-analysis. Fam Cancer. 2022;21:429&#x2013;439.</Citation></Reference><Reference><Citation>Anele CC, Martin I, McGinty Duggan PM, et al. Attenuated familial adenomatous polyposis: a phenotypic diagnosis but obsolete term? Dis Colon Rectum. 2022;65:529&#x2013;535.</Citation></Reference><Reference><Citation>Roncucci L, Pedroni M, Mariani F. Attenuated adenomatous polyposis of the large bowel: present and future. World J Gastroenterol. 2017;23:4135&#x2013;4139.</Citation></Reference><Reference><Citation>Spigelman AD, Talbot IC, Williams CB, Domizio P, Phillips RKS. Upper gastrointestinal cancer in patients with familial adenomatous polyposis. Lancet. 1989;334:783&#x2013;785.</Citation></Reference><Reference><Citation>DelSignore M, Jeong T, Denmark G, et al. Incidence and natural history of gastric high-grade dysplasia in patients with familial adenomatous polyposis syndrome. Gastrointest Endosc. 2023;97:25&#x2013;34.e6.</Citation></Reference><Reference><Citation>Knudsen AL, B&#xfc;low S, Tomlinson I, M&#xf6;slein G, Heinimann K, Christensen IJ; AFAP Study Group. Attenuated familial adenomatous polyposis: results from an international collaborative study. Colorectal Dis. 2010;12:e243&#x2013;e249.</Citation></Reference><Reference><Citation>Richards S, Aziz N, Bale S, et al.; ACMG Laboratory Quality Assurance Committee. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17:405&#x2013;424.</Citation></Reference><Reference><Citation>Yen T, Stanich PP, Axell L, et al. APC-associated polyposis conditions. Atlas Genet Cytogenet Oncol Haematol. 2022;24:477&#x2013;482.</Citation></Reference><Reference><Citation>Jin XF, Spoettl G, Mauerer J, N&#xf6;lting S, Auernhammer CJ. Inhibition of Wnt/&#x3b2;-catenin signaling in neuroendocrine tumors in vitro: antitumoral effects. Cancers. 2020;12:345.</Citation></Reference><Reference><Citation>Das S, Dasari A. Epidemiology, incidence, and prevalence of neuroendocrine neoplasms: are there global differences? Curr Oncol Rep. 2021;23:43.</Citation></Reference><Reference><Citation>Nawata Y, Ichihara S, Hirasawa D, et al. A case of gastric adenocarcinoma considered to originate from a sporadic fundic gland polyp in a Helicobacter pylori -uninfected stomach. Clin J Gastroenterol. 2020;13:740&#x2013;745.</Citation></Reference><Reference><Citation>Baptista D, Fernandes M, Garrido M, et al. Gastric polyps in familial adenomatous polyposis Portuguese patients: the first western cohort with Asian features. Pathobiology. 2024;91:196&#x2013;204.</Citation></Reference><Reference><Citation>Leone PJ, Mankaney G, Sarvapelli S, et al. Endoscopic and histologic features associated with gastric cancer in familial adenomatous polyposis. Gastrointest Endosc. 2019;89:961&#x2013;968.</Citation></Reference><Reference><Citation>Mankaney GN, Cruise M, Sarvepalli S, et al. Surveillance for pathology associated with cancer on endoscopy (SPACE): criteria to identify high-risk gastric polyps in familial adenomatous polyposis. Gastrointest Endosc. 2020;92:755&#x2013;762.</Citation></Reference><Reference><Citation>Martin I, Roos VH, Anele C, et al. Gastric adenomas and their management in familial adenomatous polyposis. Endoscopy. 2021;53:795&#x2013;801.</Citation></Reference><Reference><Citation>Arvanitis ML, Jagelman DG, Fazio VW, Lavery IC, McGannon E. Mortality in patients with familial adenomatous polyposis. Dis Colon Rectum. 1990;33:639&#x2013;642.</Citation></Reference><Reference><Citation>Iwama T, Mishima Y, Utsunomiya J. The impact of familial adenomatous polyposis on the tumorigenesis and mortality at the several organs. Its rational treatment. Ann Surg. 1993;217:101&#x2013;108.</Citation></Reference><Reference><Citation>B&#xfc;low S. Results of national registration of familial adenomatous polyposis. Gut. 2003;52:742&#x2013;746.</Citation></Reference><Reference><Citation>Ghorbanoghli Z, Bastiaansen BAJ, Langers AMJ, et al. Extracolonic cancer risk in Dutch patients with APC (adenomatous polyposis coli)-associated polyposis. J Med Genet. 2018;55:11&#x2013;14.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>